IHC-Fr, WB, Flow Cytmore details Unsuitable for:
ICC/IF,IHC-P or IP
Synthetic peptide corresponding to residues in Human IRF5 (Q13568).
U937, Ramos and THP-1 cell lysates, U937 cells.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
1/1000 - 1/10000. Detects a band of approximately 60 kDa (predicted molecular weight: 56 kDa).Can be blocked with IRF5 peptide (ab174256).
1/100 - 1/500.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
Is unsuitable for ICC/IF,IHC-P or IP.
Involvement in disease
Genetic variations in IRF5 are associated with susceptibility to inflammatory bowel disease type 14 (IBD14) [MIM:612245]. IBD14 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Genetic variations in IRF5 are associated with susceptibility to systemic lupus erythematosus type 10 (SLEB10) [MIM:612251]. Systemic lupus erythematosus (SLE) is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Genetic variations in IRF5 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.
Belongs to the IRF family. Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
Flow cytometric analysis of permeabilized U937 cells using ab124792 at 1/100 dilution (red) or a rabbit IgG (negative) (green).
Flow Cytometry - Anti-IRF5 antibody [EPR6094] (ab124792)This image is courtesy of an anonymous Abreview
Flow cytometry analysis of Plasmacytoid dendritic cells, staining IRF5 with ab124792.
Cells were fixed in paraformaldehyde and fixed in saponin. The sample was incubated with the primary antibody (1/100 in 2% human serum + 0.5 mM EDTA) for 20 minutes at 4°C. An AlexaFluor®488-conjugated goat anti-rabbit polyclonal IgG (1/100) was used as the secondary antibody.
Gating Strategy: FSC/SSC lymphocytes and then FSC-A/FSC-H singlets